Audiological follow-up in transplant patients treated with calcineurin immunosuppressants

Resumen

Background: Ototoxicity is a side effect of drugs and medications that usually leads to bilateral and symmetric sensorineural hearing loss that commonly affects the high-frequency range initially, with or preceded by tinnitus. Possible ototoxic side effects of calcineurin inhibitor immunosuppressants have been suggested, but this remains unclear. The aim of this study was to evaluate audiological changes in patients undergoing transplantation receiving immunosuppressive treatment with calcineurin inhibitors. Methods: Prospective cohort study. Adult patients undergoing liver or kidney transplantation treated with calcineurin inhibitors were included. Pure-tone audiometry, distortion product otoacoustic emissions, and the Tinnitus Handicap Inventory questionnaire were completed at baseline, one, three, and six months after transplantation. Hearing thresholds were compared and correlated with plasma concentrations of calcineurin inhibitors. Results: Seventeen patients were included, 59% males, with a median age of 54.7 years (29–68 years). Twelve patients underwent liver transplantation, four underwent kidney transplantation, and one patient underwent both. The median follow-up was 5.8 months (4–8 months). Significant pure-tone average shifts were observed in two patients. Both cases presented fluctuations in their hearing levels, which were not bilateral, symmetrical, and affecting the higher frequencies. All patients received tacrolimus within the therapeutic range during the follow-up period. Three different patients exceeded the expected range once; however, they were rapidly corrected and did not correlate with any changes in hearing. Conclusions: It appears that tacrolimus does not cause hearing loss when levels are within therapeutic range for a follow-up period of six months post-transplantation.